Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
复制标题
DOI：
10.1097/ju.0000000000001157
复制
发表时间：
2020-12-01
影响因子：
6.6
通讯作者：
Perlis, Nathan
中科院分区：
文献类型：
--
作者：
Deniffel, Dominik;Salinas, Emmanuel;Perlis, Nathan
目的：我们评估了基线多参数磁共振成像上的1级前列腺癌（GG）的可见性是否影响临床outcome.Materials和Methods：我们评估了454名在2006年至2018年期间接受多参数磁共振成像的男性，其中最大GG 1前列腺癌包括磁共振成像靶向活检。多参数磁共振成像分为阴性、可疑或阳性。评估的结果是无治疗生存率、无活检肿瘤生存率和根治性乳腺癌切除术时的不利疾病（pT 3或更高和/或GG 3或更高）。Kaplan-Meier和多变量考克斯比例风险分析用于评估多参数磁共振成像和临床病理变量（年龄，年，前列腺特异性抗原密度和活检肿瘤体积的措施）对outcomes.Results的影响：在随访期间（中位数45.2个月），61名男性在随访活检和139进行了明确的治疗疾病升级。在基线多参数磁共振成像阴性、可疑和阳性的男性中，5年无治疗生存率分别为79%、73%和49%（p
Purpose: We assessed whether the visibility of Grade Group (GG) 1 prostate cancer on baseline multiparametric magnetic resonance imaging affects clinical outcomes.Materials and Methods: We evaluated 454 men who underwent multiparametric magnetic resonance imaging between 2006 and 2018 with maximum GG1 prostate cancer inclusive of magnetic resonance imaging targeted biopsy. Multiparametric magnetic resonance imaging was graded as negative, equivocal or positive. Assessed outcomes were treatment-free survival, biopsy upgrade-free survival and unfavorable disease at radical prostatectomy (pT 3 or greater and/or GG3 or greater). Kaplan-Meier and multivariable Cox proportional hazard analyses were used to estimate the impact of multiparametric magnetic resonance imaging and clinicopathological variables (age, year, prostate specific antigen density and measures of tumor volume on biopsy) on outcomes.Results: During followup (median 45.2 months) 61 men had disease upgraded on followup biopsy and 139 underwent definitive treatment. In men with negative, equivocal and positive baseline multiparametric magnetic resonance imaging at 5 years, treatment-free survival was 79%, 73% and 49% (p